Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi(Southwest Medical University), Kongming Wu(Shanxi Medical University)
Cited by 1,422
Related Papers
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
|Molecular Cancer|2019|604
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
|Molecular Cancer|2022|458
Chimeric antigen receptor T cells: a novel therapy for solid tumors
|Journal of Hematology & Oncology|2017|306
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
|Molecular Cancer|2019|266
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
|Journal of Hematology & Oncology|2022|178